The landscape of hepatitis C treatment has undergone a fundamental transformation that extends far beyond simple drug approval timelines. This systematic analysis of prescribing patterns reveals how breakthrough antiviral therapies have reshaped not just treatment outcomes, but the entire patient population receiving care and the healthcare providers delivering it. The shift represents one of modern medicine's most dramatic therapeutic revolutions, with implications for how we approach other chronic viral infections. Direct-acting antivirals have fundamentally altered hepatitis C from a progressive, often fatal condition requiring lengthy interferon-based regimens with severe side effects to a curable infection treatable with short-course oral medications achieving cure rates exceeding 95%. The data spanning over a decade captures this transition in real-world clinical practice, documenting changes in which patients receive treatment, which specialties prescribe these medications, and how access patterns have evolved across different healthcare settings. This transformation has particular significance for longevity-focused healthcare, as hepatitis C traditionally accelerated liver aging and increased cardiovascular mortality risk. The ability to eliminate the virus entirely removes these aging accelerants from millions of patients. However, the study's findings also illuminate persistent gaps in treatment access and prescriber adoption patterns that may influence which populations benefit from this medical breakthrough. The hepatitis C treatment revolution serves as a compelling case study for how transformative therapies diffuse through healthcare systems, offering insights relevant to emerging longevity interventions and other paradigm-shifting medical technologies that promise to fundamentally alter disease trajectories.